Cargando…

PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes

The expression of Programmed death-1 (PD-1) / programmed death-ligand 1 (PD-L1) has been reported to be reliable prognostic factors in various malignances including primary nasopharyngeal carcinoma (NPC). However, the exact role of PD-1/PD-L1 in recurrent NPC remains unclear. In this study, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yajuan, Miao, Jingjing, Wu, Haijun, Tang, Hao, Kuang, Jing, Zhou, Xiaoyi, Peng, Yi, Hu, Desheng, Shi, Dingbo, Deng, Wuguo, Cao, Xinyue, Zhao, Chong, Xie, Conghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584243/ https://www.ncbi.nlm.nih.gov/pubmed/28881642 http://dx.doi.org/10.18632/oncotarget.17214

Ejemplares similares

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load
por: Zhou, Yajuan, et al.
Publicado: (2017)

Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence
por: Zheng, Jianpei, et al.
Publicado: (2023)

CTHRC1 and PD-1/PD-L1 expression predicts tumor recurrence in prostate cancer
por: Zhou, Qing, et al.
Publicado: (2019)

Survival Benefit of Adding Chemotherapy to Intensity Modulated Radiation in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
por: Ji, Xuemei, et al.
Publicado: (2013)

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma
por: Jin, Ting, et al.
Publicado: (2020)

Are PD-1 inhibitors effective for recurrent/metastatic nasopharyngeal carcinoma? Meta-analysis and systematic review
por: Yan, Le, et al.
Publicado: (2023)

NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer
por: Qin, Ge, et al.
Publicado: (2020)

Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1
por: Makowska, Anna, et al.
Publicado: (2020)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis
por: Huang, Zi-Lu, et al.
Publicado: (2019)

Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov
por: Dai, Zelei, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
por: Lin, Jing, et al.
Publicado: (2022)

Cytomembranic PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma
por: Zheng, Linfeng, et al.
Publicado: (2017)

Role of β-catenin in PD-L1 expression of nasopharyngeal carcinoma
por: Wang, Haihua, et al.
Publicado: (2023)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Friend Leukemia Virus Integration 1 Expression Has Prognostic Significance in Nasopharyngeal Carcinoma()
por: Liang, Xuexia, et al.
Publicado: (2014)

S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY
por: Zhang, Huilai, et al.
Publicado: (2023)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Predictive and prognostic role of early apolipoprotein A‐I alteration in recurrent or metastatic nasopharyngeal carcinoma patients treated with anti‐PD‐1 therapy
por: Xiao, Bi Jing, et al.
Publicado: (2023)

Interferon β and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells
por: Makowska, Anna, et al.
Publicado: (2019)

Expression of cancer cell-intrinsic PD-1 associates with PD-L1 and p-S6 and predicts a good prognosis in nasopharyngeal carcinoma
por: Zhang, Yuting, et al.
Publicado: (2021)

Comparison of Immune Checkpoint Molecules PD-1 and PD-L1 in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence
por: Yu, Wei, et al.
Publicado: (2022)

Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma
por: Tang, Yanyan, et al.
Publicado: (2017)

Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma
por: Zhao, Liang, et al.
Publicado: (2019)

Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma
por: Cao, Yabing, et al.
Publicado: (2019)

Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma
por: Zhang, Ao, et al.
Publicado: (2021)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
por: Zhou, Yanting, et al.
Publicado: (2023)

The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?
por: Jiang, Aimin, et al.
Publicado: (2022)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors
por: Fan, Zhenzhen, et al.
Publicado: (2020)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
por: Mo, Zhongfu, et al.
Publicado: (2016)

Adjunctive PD-1 inhibitor versus standard chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis
por: Polintan, Edgar Theodore, et al.
Publicado: (2022)

Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
por: Lim, Darren Wan-Teck, et al.
Publicado: (2023)

Epstein–Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma
por: Kase, Kina, et al.
Publicado: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Li, Zhitao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8l7qv4ls03l0t4qj94um0st4lt